Inhibikase Therapeutics Ownership
| IKT Stock | USD 2.73 0.37 15.68% |
Shares in Circulation | First Issued 2019-03-31 | Previous Quarter 7.5 M | Current Value 8.9 M | Avarage Shares Outstanding 3.7 M | Quarterly Volatility 2.3 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Inhibikase |
Inhibikase Stock Ownership Analysis
The company recorded a loss per share of 3.12. Inhibikase Therapeutics had not issued any dividends in recent years. The entity had 1:6 split on the 30th of June 2023. Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinsons Disease and related disorders that arise inside and outside of the brain. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia. Inhibikase Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 6 people. To learn more about Inhibikase Therapeutics call Milton Werner at 678 392 3419 or check out https://www.inhibikase.com.Besides selling stocks to institutional investors, Inhibikase Therapeutics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Inhibikase Therapeutics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Inhibikase Therapeutics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Inhibikase Therapeutics Quarterly Liabilities And Stockholders Equity |
|
Inhibikase Therapeutics Insider Trades History
About 10.0% of Inhibikase Therapeutics are currently held by insiders. Unlike Inhibikase Therapeutics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Inhibikase Therapeutics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Inhibikase Therapeutics' insider trades
Inhibikase Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Inhibikase Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Inhibikase Therapeutics backward and forwards among themselves. Inhibikase Therapeutics' institutional investor refers to the entity that pools money to purchase Inhibikase Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Susquehanna International Group, Llp | 2024-06-30 | 0.0 | Ubs Group Ag | 2024-06-30 | 0.0 | Citadel Advisors Llc | 2024-09-30 | 0.0 | Advisor Group Holdings, Inc. | 2024-06-30 | 0.0 | Redmond Asset Management, Llc | 2024-06-30 | 0.0 | Armistice Capital, Llc | 2024-09-30 | 626.5 K | Blair William & Co | 2024-06-30 | 116.1 K | Geode Capital Management, Llc | 2024-09-30 | 50.1 K | Renaissance Technologies Corp | 2024-09-30 | 19.9 K | Vanguard Group Inc | 2024-09-30 | 16.7 K | State Street Corp | 2024-06-30 | 10.1 K |
Inhibikase Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Inhibikase Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Inhibikase Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Inhibikase Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Inhibikase Therapeutics Outstanding Bonds
Inhibikase Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Inhibikase Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Inhibikase bonds can be classified according to their maturity, which is the date when Inhibikase Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| INGREDION INC 32 Corp BondUS457187AB87 | View | |
| US457187AC60 Corp BondUS457187AC60 | View | |
| US457187AD44 Corp BondUS457187AD44 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View |
Inhibikase Therapeutics Corporate Filings
| 18th of November 2024 Other Reports | ViewVerify | |
10Q | 14th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
| 8th of November 2024 Other Reports | ViewVerify | |
13A | 28th of October 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Inhibikase Stock Analysis
When running Inhibikase Therapeutics' price analysis, check to measure Inhibikase Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inhibikase Therapeutics is operating at the current time. Most of Inhibikase Therapeutics' value examination focuses on studying past and present price action to predict the probability of Inhibikase Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inhibikase Therapeutics' price. Additionally, you may evaluate how the addition of Inhibikase Therapeutics to your portfolios can decrease your overall portfolio volatility.